Skip to main content

BI breaks ground on Solids Launch facility

Boehringer Ingelheim (BI) has started the construction of a new production facility for innovative drugs. The new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. 

The research-driven pharmaceutical company is investing €85 million (US$99.3 million) in Ingelheim, focusing on modern and flexible production.

Pfizer reorganises

Pharmaceutical giant Pfizer is reorganising its company into three businesses to help the company “achieve its growth potential”. 

A science-based Innovative Medicines business will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables. These units possess significant therapeutic area expertise in the medical, commercial and patient experience domains and will provide a strong commercialisation platform for these medicines. 

Takeda and Shire settle on US$62 billion deal

After months of discussions, Japan’s Takeda Pharmaceutical Company has reached an agreement to acquire Shire for US$62 billion (see SCM, May, p.20). The acquisition is expected to create a global, R&D-driven biopharmaceutical leader headquartered in Japan and better position Takeda to deliver highly-innovative medicines and transformative care globally. The transaction is expected to close in the first half of 2019.

Madison Dearborn Partners to acquire Alcami

Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, has reached an agreement to be acquired by Madison Dearborn Partners (MDP), a leading private equity firm based in Chicago. MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation. 

The transaction is expected to be completed in the third quarter of 2018, pending customary closing conditions.

Subscribe to Pharmaceuticals

 

 

 

AMRI banner advert